Shire PLC (SHPG) Trading Down 1.2%
Shire PLC (NASDAQ:SHPG) shares were down 1.2% during trading on Wednesday . The stock traded as low as $202.55 and last traded at $204.00, with a volume of 1,681,069 shares changing hands. The stock had previously closed at $206.56.
Several research analysts have commented on SHPG shares. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 30th. Zacks Investment Research upgraded Shire PLC from a “hold” rating to a “buy” rating and set a $208.00 target price for the company in a research note on Tuesday, July 5th. Citigroup Inc. restated a “buy” rating on shares of Shire PLC in a research note on Monday. Leerink Swann restated a “buy” rating and set a $213.00 target price (down from $225.00) on shares of Shire PLC in a research note on Thursday, June 16th. Finally, Goldman Sachs Group Inc. restated a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 28th. Four research analysts have rated the stock with a hold rating and twenty-three have given a buy rating to the stock. Shire PLC has an average rating of “Buy” and a consensus price target of $230.67.
The stock has a market cap of $60.76 billion, a PE ratio of 42.39 and a beta of 1.11. The company has a 50 day moving average of $196.07 and a 200 day moving average of $183.99.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/shire-plc-shpg-trading-down-1-2.html
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The company had revenue of $2.43 million for the quarter, compared to the consensus estimate of $2.28 billion. During the same quarter in the previous year, the firm posted $2.63 EPS. The business’s revenue was up 55.9% compared to the same quarter last year. Equities analysts expect that Shire PLC will post $12.93 EPS for the current year.
The business also recently disclosed a dividend, which will be paid on Friday, October 7th. Stockholders of record on Friday, September 9th will be issued a dividend of $0.139 per share. The ex-dividend date of this dividend is Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Canal Insurance CO acquired a new stake in Shire PLC during the second quarter worth $102,000. FTB Advisors Inc. boosted its stake in Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 18 shares during the last quarter. Duncker Streett & Co. Inc. acquired a new stake in Shire PLC during the second quarter worth $111,000. Quadrant Capital Group LLC boosted its stake in Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 372 shares during the last quarter. Finally, Ropes Wealth Advisors LLC acquired a new stake in Shire PLC during the second quarter worth $114,000. Institutional investors own 24.26% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.